ExpreS2ion Biotechnologies: Expanding ES2B-C001 study to include combination testing

EXPRS2Analytikerkommentar13.05.2025, 13.04

ExpreS2ion has today announced that it has submitted a study protocol amendment to the Austrian regulatory authorities for its Phase 1 ES2B-C001 breast cancer study. The amendment aims to enable evaluation of its breast cancer vaccine candidate, ES2B-C001, in combination with antibody-drug conjugates (ADCs), and to expand the number of study sites.

In addition to increasing the number of clinical trial sites in Austria—making it more likely that the study can be completed within the expected timeline—the inclusion of ES2B-C001 in combination treatments is also expected to accelerate patient recruitment. This is because combination therapy better aligns with current treatment standards, thereby increasing the number of eligible patients.

The company also states that these changes to the protocol are not expected to affect the overall timeline, as the original trial continues under the current protocol. An update on timelines will be provided when the first patient has been dosed.

Beyond supporting the study’s timely execution, testing ES2B-C001 in combination with other treatments could also generate additional data that may strengthen the commercial potential of the vaccine, as it has future potential to be used as an add-on to currently recommended treatments.

ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. At 10:30 CET on the same day, we are hosting an event with management. In addition to the quarterly results, the discussion could focus on today’s announcement and the potential of expanding the study, as well as the prospects of the recently announced partnership with WuXi Biologics regarding the ExpreS2™ technology platform.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement.— Michael Friis, 13:03, 13-05-2025

ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen.

Læs mere på virksomhedsside